Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Authors:

Abstract
No abstract available
Funding Information
  • Roche
  • Janssen Pharmaceutica
  • Bristol-Myers Squibb

This publication has 21 references indexed in Scilit: